What to know about COVID-19 as fall approaches
Answers to some of the frequently asked questions about the virus, breakthrough infections and booster shots.
Alexander Tin is a digital reporter for CBS News based in the Washington, D.C. bureau. He covers the Biden administration's public health agencies, including the federal response to infectious disease outbreaks like COVID-19. Previously, he was a campaign reporter for CBS News based out of Las Vegas, where he was raised. He covered presidential, Senate and House candidates for the 2020 election cycle in Arizona, California, Nevada and New Mexico. He has also worked in Washington for "Face the Nation" and in New York for the "CBS Evening News." Tin graduated from Columbia University in 2017 with a bachelor's degree in political science.
Answers to some of the frequently asked questions about the virus, breakthrough infections and booster shots.
Health officials hope the move could help reverse the nationwide slowdown in vaccinations.
Both the drug maker and an NIH trial could have results for recipients of the single-shot vaccine soon.
The vaccines appear to remain effective against severe illness or hospitalization from COVID-19 for most people.
U.S. scientists are investigating whether fully vaccinated people are experiencing different symptoms with the Delta variant than with prior variants.
News of the move comes as the CDC's independent panel of vaccine advisers is scheduled to meet Friday morning to discuss "additional doses in immunocompromised individuals."
The country was averaging around 441,198 new vaccinations per day as of August 5, a 95% increase from July 5.
Some 274 vaccinated people came down with symptoms of COVID-19 after an outbreak in Massachusetts, the CDC said.
Data in the document underscores the danger posed by the mutant strain of the virus first spotted in India
The CDC also said masks should be required of everyone inside K-12 schools.
The drug maker plans to expand the size of its trial to look for "rarer events" of side effects.
As early as this fall, U.S. regulators could decide whether some people should get booster shots.
The decision comes after federal health officials identified a very rare pattern of the potentially serious nervous system disorder in some recipients of the vaccine.
The U.S. is currently averaging less than 300,000 first doses daily, according to figures published by the CDC.
The Centers for Disease Control and Prevention said this would be its "final extension."